Results 101 to 110 of about 7,662 (208)

Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure

Medicina, 2019
Dabigatran etexilate is a direct oral anticoagulant (thrombin inhibitor) used for the prevention of stroke and systemic thromboembolic events in patients with permanent atrial fibrillation; prevention of venous thromboembolic events and deep veins ...
Gintautas Gumbrevičius, Gytė Damulevičienė, Vaidotas Galaunė, Milda Gumbrevičiūtė   +3 more
doaj   +1 more source

Sangrado rectal tras la administración de Dabigatrán [PDF]

, 2013
Presentamos el caso de tres pacientes intervenidos de prótesis total de cadera, que tras la administración protocolaria de tromboprofilaxis con Dabigatrán, presentaron un sangrado rectal importante, siendo este la primera manifestación de un cáncer ...
Díaz de Rada, P., Muñoa, L., Riva, S. de la   +2 more
core  

Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland [PDF]

, 2012
Objectives: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not require INR monitoring.
Eichler, Klaus, Plessow, Rafael, Pletscher, Mark, Wieser, Simon   +3 more
core   +1 more source

DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS

Атеротромбоз, 2015
This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC).
N. M. Vorobieva, E. P. Panchenko
doaj   +1 more source

Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults. [PDF]

Eur J Pharm Sci, 2023
Sia JEV, Lai X, Wu X, Zhang F, Li H, Cui C, Liu D.   +6 more
europepmc   +1 more source

Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants [PDF]

, 2017
New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use.
Adusumilli, P.K., Adepu, R.,, Al Hamid, A., Ghaleb, M., Aljadhey, H., Aslanpour, Z.,, Alhomoud, F., Dhillon, S., Aslanpour, Z., Smith, F.,, Andreica, I., Grissinger, M.,, Basger, B. J., Moles, R. J., Chen, T. F.,, Bauer, K. A.,, Beijer HJ,, Beyer-Westendorf, J., Ebertz, F., Foerster, K., Gelbricht, V., Michalski, F., Köhler, C., Werth, S., Endig, H., Pannach, S., Tittl, L., Sahin, K., Daschkow, K., Weiss, N.,, Caldeira, D., Barra, M., Santos, A. T., de Abreu, D., Pinto, F.J., Ferreira, J.J., Costa, J.,, Caldeira, D., Canastro, M., Barra, M., Ferreira, A., Costa, J., Pinto, F.J., Ferreira, J.J.,, Caldeira, D., Gonçalves, N., Pinto, F. J., Costa, J., Ferreira, J.J.,, Camm, A. J., Lip, G. Y., De Caterina, Savelieva, I., Atar, D., Hohnloser, S.H., Hindricks, G., Kirchhof, P., Chan, Y. H., Yen, K. C., See, L. C., Chang, S.H., Wu, L.S., Lee, H.F., Tu, H.T., Yeh, Y.H., Kuo, C.T.,, Chang, H. Y., Zhou, M., Tang, W., Alexander, G.C., Singh, S.,, Chatterjee, S., Sardar, P., Giri, J. S., Ghosh, J., Mukherjee, D.,, Crowther, M. A., Warkentin, T. E., Cutler, T. W., Chuang, A., Huynh, T. D., Witt, R.G., Branch, J., Pon, T., White R.,, Dentali, F., Riva, N., Crowther, Turpie, A.G., Lip, G.Y., Ageno, W.,, Dentali, F., Sironi, A. P., Gianni, M., Orlandini, F., Guasti, L., Grandi, A.M., Franchini, M., Ageno, W., Squizzato, A.,, Donaldson, M., Norbeck, A. O., Forslund, T., Wettermark, B., Hjemdahl, P., Gorst-Rasmussen, A., Skjøth, F., Larsen, T. B., Rasmussen, L.H., Lip, G.Y., Lane, D.A.,, Graham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M.R., Levenson, M., Sheu, T.C., Mott, K., Goulding, M.R., Houstoun, M., MaCurdy, T.E., Worrall, C., Kelman, J.A.,, Ho, M. H., Ho, C. W., Cheung, E., Chan, P.H., Hai, J.J., Chan, K.H., Chan, E.W., Leung, G.K., Tse, H.F., Siu, C.W.,, Holster, I. L., Valkhoff, V. E., Kuipers, E. J., Tjwa, ETTL,, Hu, Y. F., Liao, J. N., Chern, C. M., Weng, C.H., Lin, Y.J., Chang, S.L., Wu, C.H., Sung, S.H., Wang, K.L., Lu, T.M., Chao, T.F., Lo, L.W., Chung, F.P., Hsu, L.C., Chen, S.A.,, Hughes, R. G., Blegen, M. A., Landefeld, C. S., Beyth, R. J., Larsen, T. B., Rasmussen, L. H., Skjøth, F., Due, K.M., Callréus, T., Rosenzweig, M., Lip, G.Y.,, Lee, P. Y., Han, S. Y., Miyahara, R. K., Lega, J. C., Bertoletti, L., Gremillet, C., Chapelle, C., Mis-metti, P., Cucherat, M., Vital-Durand, D., Laporte, S.,, Martinez, C., Katholing, A., Wallenhorst, C., Freedman, S.B.,, Mekaj, Y. H., Mekaj, A. Y., Duci, S. B., Miftari, E.I.,, Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J., Monteagudo, M., Fernández-Díaz, E., García-García, J., Ayo-Martín, O., Hernández-Fernández, F., Segura, T.,, Nishtala, P. S., Gnjidic, D., Jamieson, H. A., Hanger, H.C., Kaluarachchi, C., Hilmer, S.N.,, Plovanich, M., Mostaghimi, A.,, Saedder, E. A., Brock, B., Nielsen, L. P., Bonnerup, D.K., Lisby, M.,, Sardar, P., Chatterjee, S., Chaudhari, S., Lip, G.Y.,, Sardar, P., Chatterjee, S., Lavie, C.J., Giri, J.S., Ghosh, J., Mukherjee, D., Lip, G.Y., Scridon, A., Constantin, S. R.,, Strand, L, Morley P, Cipolle R, et al., Thorne, K., Jayathissa, S., Dee, S., Briggs, N., Taylor J., Reid, S., De Silva, K., Dean, J.,, Van den Bemt, P. M. L. A., Egberts, A. C. G., Van Mil, J. F., Westerlund, L. T., Hersberger, K. E., Schaefer, M.A.,   +44 more
core   +2 more sources

Design of small-molecule active-site inhibitors of the S1A family proteases as procoagulant and anticoagulant drugs [PDF]

, 2017
Vitamin K antagonists (VKA) have long been the default drugs for anticoagulant management in venous thrombosis. While efficacious, they are difficult to use due to interpatient dose–response variability and the risks of bleeding.
Banner D. W., Bode W., Budovich A., Cool D. E., Fritz H., Giansily-Blaizot M., Himber J., Mather T., Peter M. Fischer, Sun W. Y.   +9 more
core   +2 more sources

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage

Clinical Practice and Cases in Emergency Medicine, 2017
Dabigatran etexilate mesylate is a direct thrombin inhibitor used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Jonathan Balakumar, Ruben Santiago, Mark Supino   +2 more
doaj   +1 more source

Use of oral anticoagulants after intramedullary nailing of femur and tibial fractures in trauma department

Travmatologiâ i Ortopediâ Rossii, 2016
The authors evaluated of the effectiveness of new oral anticoagulants in patients with diaphyseal fractures of the femur and tibia.We analyzed the effectiveness of thromboprophylaxis in 85 patients with diaphyseal fractures of the femur and tibia in the ...
A. K. Dulaev, A. N. Tsed, I. G. Dzhusoev
doaj  

Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate. [PDF]

CPT Pharmacometrics Syst Pharmacol, 2021
Farhan N, Cristofoletti R, Basu S, Kim S, Lingineni K, Jiang S, Brown JD, Fang LL, Lesko LJ, Schmidt S.   +9 more
europepmc   +1 more source